On September 3, 2019 Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex immunogene therapy, to market (Press release, Genprex, SEP 3, 2019, View Source [SID1234539234]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website.

"These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most," said Rodney Varner, Chairman and Chief Executive Officer of Genprex. "We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer ("NSCLC") and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization."

Anticipated milestones and future guidance:

2H 2019

Establish scalability parameters of new, optimized manufacturing method for lipid nanoparticle delivery system as part of new Genprex research and development program
Complete protocol for Oncoprex + immunotherapy clinical trial
Prepare and file IND for Oncoprex + immunotherapy clinical trial
Determine clinical site selection, expansion strategy and contract with clinical sites for Oncoprex + erlotinib clinical trial
1H 2020

Complete manufacturing scale-up to support trial site expansion and commercial-scale development
Complete preparation of lipid nanoparticle delivery system and TUSC2 DNA plasmid for clinical expansion
Contract with new clinical trial sites for Oncoprex + immunotherapy clinical trial
Begin enrolling patients at new clinical sites for Oncoprex + immunotherapy clinical trial
In addition to the milestone updates, Genprex also unveiled in its updated corporate presentation, an overview of the limitations to current NSCLC treatment and a swimmer plot demonstrating results to date of its Phase I/II clinical trial administering Oncoprex in combination with erlotinib against NSCLC. Genprex also recently launched a new interactive timeline on its website where visitors can follow the company’s success since its inception.

On September 3, 2019 Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, reported the appointment of Shakti Narayan, J.D., Ph.D., as its Chief Executive Officer and a member of the Board of Directors (Press release, accent therapeutics, SEP 3, 2019, View Source [SID1234539233]). Dr. Narayan brings a strong record of experience in life sciences, having held various leadership roles which led to transformational achievements within both the biotechnology and pharmaceutical industries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Accent is defining a new and practical paradigm for addressing RNA pathobiology by targeting the proteins that control many aspects of RNA biology, unlocking the potential of RNA biology and providing new hope for patients," said Robert A. Copeland, Ph.D., President and Chief Scientific Officer of Accent. "We are delighted to welcome Shakti to Accent. He brings a wealth of biopharma experience and leadership as we advance our leading position in the field of RNA modification."

"Accent has made incredible progress developing a pipeline of targeted therapies in this novel area of biology and is well-positioned to accelerate its impact in the field," said Dr. Narayan. "I’m thrilled to be joining the exceptional team at Accent as we work to better the course of cancer treatment for patients."

Dr. Narayan was most recently Chief Business Officer of Tango Therapeutics, where he was responsible for business development, finance and various operational functions. During his tenure at Tango, he led a $1.7B transformational partnership with Gilead Sciences. Prior to Tango, Dr. Narayan was Vice President, Head of Transactions at Johnson & Johnson Innovation, where he helped build J&J’s Innovation Centers model, led oncology business development efforts and led a team of dealmakers who drove transactions for multiple J&J businesses. Prior to his time at J&J, Dr. Narayan led business development as part of the management team at Nodality, a VC-backed personalized medicine biotechnology company, where he developed the company’s partnering strategy, led and closed multiple strategic collaborations and held various operational roles.

Dr. Narayan’s career began in business development at Genentech and as a life sciences transactional attorney at Wilson Sonsini Goodrich & Rosati. Dr. Narayan earned his Bachelor of Arts in biology from Grinnell College, obtained his Ph.D. in cellular and molecular biology at the University of Wisconsin Madison and the Salk Institute and was a post-doctoral scientist at Stanford University. His legal studies were completed at the University of California Berkeley School of Law, where he earned a J.D.

On September 3, 2019 Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported presentations at the following investor conferences during the months of September and early October (Press release, Exicure, SEP 3, 2019, View Source [SID1234539232]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 21st Annual Global Investment Conference
Corporate update
Presented by: CEO David Giljohann
Monday, September 9, 2019 at 10:25am ET
Location: New York, NY
Ladenburg Thalmann 2019 Healthcare Conference
Corporate update
Presented by: CEO David Giljohann
Tuesday, September 24, 2019 at 1:30pm ET
Location: New York, NY
Chardan’s 3rd Annual Genetic Medicines Conference
Corporate update
Presented by: Dr. David Giljohann
Monday, October 7, 2019 at 2:00pm ET
Location: New York, NY

The Next Big Thing in Genetic Medicines
Panelist: Dr. David Giljohann
Tuesday, October 8, 2019 at 9:30am ET
Location: New York, NY
An audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.

On September 3, 2019 Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, reported that it has appointed Dr Soren Bregenholt as Chief Executive Officer (Press release, Macrophage Pharma, SEP 3, 2019, View Source [SID1234539231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: "The Board is delighted to have attracted Søren to Macrophage Pharma. Soren’s outstanding track record from executive positions in both biotech and pharma, as well as his extensive expertise and insight in immunology, will be invaluable as we further develop and commercialise our proprietary Esterase Sensitive Motif (ESM) platform and evolve Macrophage Pharma into a leading biotech company."

Dr Søren Bregenholt, CEO of Macrophage Pharma, said: "I am excited to join Macrophage Pharma as CEO. The Company’s unique and proprietary ESM technology platform is a compelling strategy for inducing transcriptional reprofiling of monocytes and macrophages and represents a differentiated approach to modulation of a centrally important regulator of the immune response across a variety of human diseases. I look forward to working with management and Board to unlock the full therapeutic and commercial potential of the technology in both cancer and non-cancer fields."

Søren Bregenholt PhD is a Danish national with an extensive operational and strategic track record from the biotech and pharmaceutical industries. He previously held senior executive roles including COO and CBO at Danish biotech companies Symphogen and IO Biotech, respectively. As part of the global R&D Management at Novo Nordisk, Søren was responsible for the global R&D Strategy and External Innovation efforts. Currently, Søren serves as Chairman of the Board at the Danish-Swedish life science organization Medicon Valley Alliance. His academic career, at the University of Copenhagen and Institute Pasteur, Paris, has focussed on immunoregulation and immunopathology in cancer and other diseases.

On September 3, 2019 Selvita (WSE: SLV) reported that Pawel Przewiezlikowski, Chief Executive Officer, will present at the following conferences in New York (Press release, Selvita, SEP 3, 2019, View Source [SID1234539230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 21st Annual Global Investment Conference, Sept. 8-10, 2019
Location: Lotte New York Palace Hotel
Date/Time: Monday, Sept. 9, at 5:30 p.m. EDT
Webcast: A live and archived webcast of this presentation will also be made available at View Source

Event: Rambam Foundation Life Sciences Symposium, Sept. 10, 2019
Location: The YJP Mansion
Date/Time: Tuesday, Sept. 10, at 9:15 a.m. EDT